Eli Lilly and Co.: Drug Development Strategy (A)
Below are the available bulk discount rates for each individual item when you purchase a certain amount
Register as a Premium Educator at hbsp.harvard.edu, plan a course, and save your students up to 50% with your academic discount.
Publication Date:
October 04, 1997
Industry:
Pharmaceuticals
Industry:
Manufacturing
Source:
Harvard Business School
Describes how Eli Lilly and Co. tries to accelerate its new drug development process with the aid of “combinatorial chemistry”–a rapidly emerging and revolutionary approach to preclinical drug discovery. The product manager of a potential blockbuster migraine drug faces the decision of “racing” the drug to market or spending additional time to refine an already promising drug candidate. Focuses on: (1) the new drug development process with an emphasis on pre-clinical drug discovery; (2) radical innovations (“combinatorial chemistry”) in the drug discovery process; (3) the managerial challenges of introducing such innovations into a large organization with multiple stakeholders; (4) the financial value of time-to-market; and (5) the changing competitive environment in the pharmaceutical industry.
If you’d like to share this PDF, you can purchase copyright permissions by increasing the quantity.
Copyright © 2020 Harvard Business School Publishing. All rights reserved. Harvard Business Publishing is an affiliate of Harvard Business School.
Eli Lilly and Co.: Drug Development Strategy (A)
Research & References of Eli Lilly and Co.: Drug Development Strategy (A)|A&C Accounting And Tax Services
Source